header logo image

Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn’t come cheap – Endpoints News

November 3rd, 2020 6:54 pm

Big Pharma execs usually dont just fade away. Sometimes, they jump to the money side of the biotech business, like Chris Viehbacher and Olivier Brandicourt. Some stick with a batch of mentoring board seats. Joe Jimenez not only plans to do both, hes also going biotech entrepreneur and starting his own play in style.

A week ago, Jimenez and his close partner Mark Fishman, who got to know each other well during their respective time as CEO and early-stage NIBR chief at Novartis, filed papers with the SEC noting that their Aditum Bio Fund I had raised the $133,040,000 they had targeted more than a year ago.

Unlock this story instantly and join 93,200+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Here is the original post:
Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn't come cheap - Endpoints News

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick